Semax peptide research: BDNF, ischemia models and evidence limits
Evidence summary: Semax is the synthetic heptapeptide Met-Glu-His-Phe-Pro-Gly-Pro, built from ACTH(4-7) with a Pro-Gly-Pro tail. Its most cited evidence concerns neurotrophin gene expression and cerebral ischemia in rat models. Human evidence is limited to Russian clinical reports and does not meet the scale or replication standards of a modern FDA approval programme.
Key findings
- Semax is an ACTH-fragment peptide but does not reproduce full ACTH's corticosteroid-releasing activity in laboratory models.
- BDNF and NGF findings are measurements of gene expression in rodent tissues, not proof of a cognitive effect in people.
- Most mechanistic studies come from related Russian research groups and need broader independent replication.
Structure and research identity
Semax combines the ACTH(4-7) sequence Met-Glu-His-Phe with Pro-Gly-Pro, a C-terminal extension designed to slow enzymatic degradation. It is often described as an ACTH(4-10) analog, although its final three residues are a stabilising sequence rather than the native ACTH residues.
That structural description is more precise than treating Semax as ACTH itself. The short fragment is studied for neural and stress-related effects, not for the endocrine activity of the full hormone.
What the BDNF and NGF study measured
Shadrina and colleagues measured the time course of BDNF and NGF gene expression after Semax exposure in rat hippocampus, frontal cortex and retina. The result supports a neurotrophin-related research mechanism in those tissues.
Gene expression is an intermediate laboratory endpoint. It does not establish improved memory, mood or recovery in humans, and it does not show that every tissue or exposure produces the same response.
Evidence from cerebral ischemia models
Rat ischemia-reperfusion studies used transcriptomic methods to examine broad changes after Semax. Reported shifts included immune-response, inflammation-related and cell-death pathways. Later proteomic work examined whether protein-expression patterns aligned with those transcript findings.
These models are useful for mapping biological responses after experimental ischemia, but they are not equivalent to a clinical treatment trial. Species, injury model, timing and outcome selection all limit translation.
Human reports and evidence quality
Russian-language clinical reports describe Semax use in ischemic stroke. They show that human administration has been reported, but the evidence base lacks large, independently replicated, blinded and placebo-controlled Western trials.
No claim about clinical efficacy, cognitive enhancement or long-term safety should be inferred from rodent molecular findings alone.
Questions a laboratory study should answer
An interpretable study should specify the Semax sequence, model, tissue, exposure timing and whether the endpoint is gene expression, protein abundance, histology or behaviour. Those endpoints answer different questions and should not be collapsed into one generalized claim.
Include appropriate controls and report the lot, purity and storage history. Replication outside the originating research network is especially important for establishing robustness.
Continue to the full evidence guide
Read the complete Semax research guide
Frequently asked questions
What is Semax peptide?
Semax is a seven-amino-acid synthetic peptide built from ACTH(4-7) plus a Pro-Gly-Pro tail.
Does Semax increase BDNF?
Rat studies reported changes in BDNF gene expression in specific tissues. That is not proof of a human cognitive or clinical effect.
What are the main Semax research models?
The literature reviewed here focuses on rat cerebral-ischemia, neurotrophin, stress and behavioural models.
Is there strong human evidence for Semax?
Human reports exist, but large independently replicated blinded trials are lacking.
Is Semax for human use?
No. PeptidesDirect supplies Semax strictly for laboratory research, not human or veterinary use.
Primary references
- Shadrina M, et al. Comparison of the temporary dynamics of NGF and BDNF gene expression in rat tissues under Semax action. J Mol Neurosci. 2010. PubMed 19662538
- Medvedeva EV, et al. Semax regulates expression of immune response genes during ischemic brain injury in rats. Mol Genet Genomics. 2017. PubMed 28255762
- Filippenkov IB, et al. Protective properties of ACTH(4-7)PGP following cerebral ischaemia-reperfusion in rats. Genes (Basel). 2020. PubMed 32580520
Related research materials
Research Use Only. Not for human or veterinary use. This page is not dosing or medical guidance.
